尼可地尔联合替格瑞洛对急性ST段抬高型心肌梗死患者心功能和预后的影响  

Effect of nicorandil combined with ticagrelor on cardiac function and prognosis of patients with acute ST-segment elevation myocardial infarction

作　　者：何蕊[1] 苏英杰 林航 HE Rui;SU Yingjie;LIN Hang(Department of Emergency Medicine,Changsha Central Hospital Affiliated to Nanhua University,Changsha 410018,China)

机构地区：[1]南华大学附属长沙中心医院急诊医学科,湖南省长沙市410018

出　　处：《临床合理用药杂志》2023年第6期1-3,7,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的 观察尼可地尔联合替格瑞洛对急性ST段抬高型心肌梗死患者心功能和预后的影响。方法选取2020—2021年南华大学附属长沙中心医院诊治的急性ST段抬高型心肌梗死患者80例,利用随机数字表法分为参考组与试验组,各40例。参考组予以替格瑞洛片,试验组在参考组基础上予以尼可地尔片。2组均持续治疗1周。比较2组临床疗效,治疗前后红细胞参数[红细胞体积(MCV)、血红蛋白浓度(MCHC)及红细胞血红蛋白量(MCH)]、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、心率(HR)],冠状动脉再通以及心绞痛发生情况,不良反应。结果 试验组治疗总有效率为95.00%,高于参考组的72.50%(χ^(2)=5.165,P=0.023)。治疗1周后,2组MCV、MCHC、MCH及LVEDD、HR低于治疗前,且试验组低于参考组(P<0.01);治疗1周后,2组LVEF高于治疗前,且试验组高于参考组(P<0.01)。试验组冠状动脉再通率高于参考组,心绞痛发生率低于参考组(P<0.05)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 尼可地尔联合替格瑞洛对急性ST段抬高型心肌梗死患者心功能和预后的影响明显,其能有效提高心功能,改善机体红细胞参数,减少临床症状,且安全性较高。Objective To observe the effect of nicorandil combined with ticagrelor on cardiac function and prognosis of patients with acute ST-segment elevation myocardial infarction. Methods A total of 80 cases of patients with acute ST-segment elevation myocardial infarction were selected from 2020 to 2021 in Changsha Central Hospital Affiliated to Nanhua University, which were divided into reference group and experimental group by random number table method, with 40 cases in each group. The reference group was given ticagrelor tablets, and the experimental group was given nicorandil tablets on the basis of the reference group. Both groups were treated for 1 week. Clinical efficacy, red blood cell parameters(MCV, MCHC and MCH), cardiac function indicators(LVEF, LVEDD, HR) before and after treatment of 1 week, coronary artery recanalization, incidence of angina pectoris and adverse reactions were compared between the two groups. Results The total effective rate of the experimental group was 95.00%, was higher than 72.50% of the reference group(χ^(2)=5.165, P=0.023). After 1 week of treatment, the MCV, MCHC, MCH, LVEDD and HR in the two groups were lower than those before treatment, and those in the experimental group were lower than reference group(P<0.01);after 1 week of treatment, LVEF of the two groups was higher than that before treatment, and LVEF in the experimental group was higher than that in the reference group(P<0.01). The coronary artery recanalization rate in the experimental group was higher than that in the reference group, and the incidence of angina pectoris was lower than that in the reference group(P<0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups(P>0.05). Conclusion Nicorandil combined with ticagrelor has significant effects on cardiac function and prognosis in patients with acute ST-segment elevation myocardial infarction, it can effectively improve patients′ cardiac function, improve red blood cell parameters, reduce clinical symptom

关 键 词：急性ST段抬高型心肌梗死 尼可地尔 替格瑞洛 心功能 预后 

分 类 号：R542.22[医药卫生—心血管疾病]